Business
Three Top European Sites Adopt Bionano Saphyr® for Cancer, Genetics, and Cytogenetic Applications
Curie Institute in France, NHS Lothian Edinburgh in Scotland, and MVZ Martinsried in Germany choose Bionano to solve unanswered questions in human genetic
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Curie Institute in France, NHS Lothian Edinburgh in Scotland, and MVZ Martinsried in Germany choose Bionano to solve unanswered questions in human genetic variation and in cytogenetic applications\nSAN DIEGO, March 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the following top European institutions have recently incorporated the Saphyr® system into their repertoire of solutions for genome analysis and are now operating them across a range of applications: Curie Institute in Paris, France; NHS Lothian in Edinburgh, Scotland; and MVZ Martinsried in Munich, Germany. The Saphyr system is designed to enable comprehensive analysis of genome structure, including genomic structural variations unresolved by current next-generation sequencing (NGS) technology. With these installations, the total number of Saphyr systems installed at customer sites to date is 84.\n The Saphyr system was adopted by MVZ Martinsried in Munich, Germany, in connection with an agreement reached in October 2019 to evaluate Saphyr for applications in different areas of cancer research and cytogenetics and to provide access to the system to neighboring research and diagnostic centers. Training and installation has been completed at MVZ, which is part of Medicover, a leading international healthcare and diagnostic service company, operating a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories in Germany. MVZ has collected data for its first cohort and begun data analysis. The Center for Human Genetics and Laboratory Diagnostics at MVZ is expected to establish Saphyr into its ISO 17501 environment for the analysis of patient samples with genetic disorders and for immunogenetic analysis of the HLA locus after transplant. MVZ is also using Saphyr for the analysis of cancer genomes in solid tumors and in collaboration with Munich Leukemia Laboratory (MLL) in leukemias. The Institut Curie in Paris purchased a Saphyr system in January 2020 thanks to the support of Region Ile de France. The system has now been installed and the lab fully trained. David Gentien, head of Curie’s Genomics Platform, commented: “We are excited to bring Bionano to Curie to improve our understanding of genome organization and structure in multiple aspects of cancer biology, in rare disease, and for basic research. W...